Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

Alliance Medical: Initial public offering will await FDA clearance of five additional 510(k) submissions for reprocessed disposable medical devices, the firm said. The Phoenix company, which has already received clearances for 15 out of 20 510(k)s submitted to the agency, withdrew its August 2001 IPO registration statement March 15. "We feel that conditions for raising money from the public market will be better after FDA has acted on our remaining 510(k) submissions," Alliance explained in a release...

You may also be interested in...



Given M2A Has Higher Diagnostic Yield Compared With Other Tests – CEO

Given Imaging is looking to tap into a $15 mil. U.S. irritable bowel syndrome (IBS) diagnostic market with an upcoming generation of the M2A wireless endoscopy imaging capsule with motility features

MedSource Technologies IPO Builds On Device Industry Outsourcing Trend

Engineering and manufacturing service provider MedSource Technologies is counting on continued growth of the U.S. medical device outsourcing market of about 17% annually as the firm moves toward a planned initial public offering of up to $138 mil

Roche To Appeal $505 Mil. Jury Decision Granting Igen Elecsys Rights

Igen International will gain the rights to Roche Diagnostic's Elecsys diagnostic product line under a $505 mil. verdict reached Jan. 10 in Maryland federal court

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT016252

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel